Polygenic risk scores, rare pathogenic variants, and family history — integrated into one clinician-ordered report, calibrated across ancestries, for cardiometabolic and renal conditions.
A prevention-focused PRS panel (ARC-PREVENT) for proactive screening, alongside six indication-anchored ARC tests that integrate polygenic risk with family history and/or rare-variant analysis for patients with a confirmed diagnosis or established risk factor.
Scores are computed with the PRSMix ensemble method and calibrated on genotype-derived principal components projected to a multi-ancestry reference exceeding 100,000 individuals, supporting wide applicability across ancestrally varied populations.
Every report is signed out by the clinical laboratory director. Analytic and clinical validity are documented against defined action thresholds — not presented as certainty where the evidence is provisional.
01
The Care Team places the order in the ARC-OMIX portal and provides clinical data through standardized questions at the time of ordering.
02
Blended Genome-Exome (BGE) sequencing on one specimen through our partner lab — supporting both rare-variant identification and genome-wide polygenic scoring.
03
Polygenic burden, monogenic status, and family history are combined on a version-locked pipeline into an absolute-risk estimate anchored to the relevant clinical comparator.
04
A thorough report with clinical decision support delivered to the ordering provider.
A sample undergoes BGE sequencing, integrated genomic risk is computed using ARC-OMIX proprietary algorithms, and returned with clinical decision support.
Our first two tests are available now.